Revolution Medicines Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team. And pleased to introduce from Revolution Medicines, we have Mark Goldsmith, Chief Executive Officer; and Peg Horn, Chief Operating Officer. Welcome.
Maybe start with a very quick overview of where Revolution Medicines is in executing on your vision. So it's such a powerful platform and it feels like we're just getting started.
Well, thanks. Thanks very much for the opportunity to be here. Revolution Medicines seeks to be an organization that designs, develops, and deploys into the clinic, innovative targeted therapeutics, particularly focused on RAS cancers, as you know.
We have today four compounds in the clinic. Two of those are direct RAS inhibitors of the form that we call RAS(ON) inhibitors, both of which are in first-in-human studies. We also have two RAS companion inhibitors that are designed to be used in combination with those RAS(ON)
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
